Cureit/AcuminTM, given in well-tolerated doses, was previously shown to reduce disease activity and suppress CRP and RF in a small randomized, placebo-controlled clinical trial in RA patients [33]. The gene discussed is CRP; the disease is rheumatoid arthritis.